There are currently 179 active clinical trials seeking participants for Heart Failure research studies. The states with the highest number of trials for Heart Failure participants are California, Florida, Texas and Pennsylvania.
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
NCT03560323
Recruiting
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose in type 2 diabetic patients with Class II-III New York Heart Association (NYHA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/30/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Heart Failure, Type 2 Diabetes Mellitus
Register for Updates
Impella Reverse Remodeling in End-Stage Heart Failure
NCT06800716
Recruiting
This observational study is being done to learn more about heart attack recovery in patients supported with the Impella 5.5 left ventricular assist device (LVAD) as part of their standard of care. There are three stages in this study: screening, treatment and post treatment. There will be two phases of enrollment: First phase will enroll 10 patients; second phase will enroll an additional 40 patients. Approximately 50 participants will take part in the study at Columbia University Irving Medical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Columbia University, New York, New York
Conditions: Heart Failure, Cardiomyopathy
Register for Updates
Get With The Guidelines-Heart Failure Registry
NCT02693509
Recruiting
Get With The Guidelines-Heart Failure is designed to improve the quality of care in patients hospitalized with heart failure. The program aims to help ensure that eligible patients are initiated on guideline recommended therapies and receive appropriate counseling prior to hospital discharge.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
01/27/2025
Locations: Amy Bennett, Dallas, Texas
Conditions: Heart Failure
Register for Updates
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
NCT04262830
Recruiting
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with... Read More
Gender:
ALL
Ages:
Between 13 years and 39 years
Trial Updated:
01/24/2025
Locations: Rady Children's Hospital, San Diego, California
Conditions: Cardiotoxicity, Pediatric Cancer, Heart Failure
Register for Updates
Effectiveness of Outpatient Intravenous Diuretic Therapy for Treatment of Worsening Heart Failure (OUTPATIENT-WHF)
NCT05704595
Recruiting
The purpose of the OUTPATIENT-WHF study is to characterize the effectiveness of outpatient intravenous diuretic therapy as a treatment for worsening heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Heart Failure
Register for Updates
Assessment of CCM in HF with Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Grandview Medical Group Research, LLC, Birmingham, Alabama +101 locations
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure
NCT04999995
Recruiting
Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinating proteins (such as UCHL1) reverses this process. Studies have demonstrated deubiquitination to be linked to certain pathological processes, such as heart failure. UCHL1 will be examined as a potenti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia, South Carolina
Conditions: Heart Failure, Dyspnea; Cardiac
Register for Updates
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence
NCT05860348
Recruiting
The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Aurora Denver Cardiology Associates, Aurora, Colorado +2 locations
Conditions: Heart Failure
Register for Updates
The STOP-MED CTRCD Trial
NCT06183437
Recruiting
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +9 locations
Conditions: Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Register for Updates
Sensor-controlled Digital Game for Heart Failure Self-management: A Clinical Trial
NCT05056129
Recruiting
This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of weight monitoring and physical activity in adults with heart failure (HF). Half of the participants will receive the SCDG app and weight monitoring and physical activity sensors and the other half will receive only the weight monitoring and physical activity sensors.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
01/16/2025
Locations: The University of Texas Austin, Austin, Texas
Conditions: Heart Failure
Register for Updates
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT04363697
Recruiting
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: TIMI Study Group, Boston, Massachusetts
Conditions: Acute Heart Failure, Heart Failure
Register for Updates
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031
Recruiting
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/15/2025
Locations: Emory University, Atlanta, Georgia +6 locations
Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure
Register for Updates